/** blogpostTitle: Gland Pharma Q1 FY27: A stronger quarter, and a longer runway */

Gland Pharma Q1 FY27: A stronger quarter, and a longer runway

Gland Pharma began FY27 with a sharp improvement in reported performance. Consolidated revenue from operations rose to INR 18,003 million in Q1 FY27, a 20% year-on-year increase. Profitability moved up faster than revenue. EBITDA was INR 4,930 million with a 27% margin, and adjusted EBITDA was INR 5,102 million with a 28% margin. Profit after tax came in at INR 3,170 million, up 47% year on year, with an 18% margin.

The quarter’s tone was set by two themes that management repeated through the investor presentation and the earnings call: steady execution in the existing injectables portfolio, and a deliberate move towards larger, longer-duration CDMO relationships. The company also continued to invest in complex product development, spending INR 772 million on R&D, about 4% of consolidated revenue.

A balanced quarter across CDMO and B2B

Gland’s business split stayed evenly balanced in Q1 FY27. CDMO revenue was INR 8,915 million and B2B revenue was INR 9,088 million. Both segments grew around 20% year on year, and each contributed 50% of quarterly revenue.

Management attributed CDMO growth to recent product launches and the progression of existing commercial programs. In B2B, growth was linked to increased demand from existing customers, new contract wins and higher volumes across several products.

The balance matters because it gives the company two levers at the same time: CDMO provides longer visibility when relationships mature, and B2B keeps the base portfolio active through volume-led execution.

Geography: the US led the growth, RoW stayed mixed

The US remained the largest contributor. Q1 FY27 US revenue was INR 9,810 million, up 32% year on year, and accounted for 54% of total revenue as shown in the presentation. Growth in the US was driven by CDMO launches and higher volumes in existing products. Management specifically called out encouraging traction in launches such as Multi-Vitamin and Dalbavancin, and volume expansion in products including Enoxaparin, Vancomycin, Chlorthiazide and Heparin.

Europe revenue was INR 3,954 million, a 20% year-on-year increase. Europe was largely CDMO-led, with CDMO revenue of INR 3,916 million and B2B of INR 38 million.

Other core markets (Canada, Australia and New Zealand) were weaker at INR 534 million, down 28% year on year, with CDMO down 45%. Rest of World revenue was INR 3,039 million, up 2% year on year.

In the call, management added context for the RoW performance. It said revenues were impacted by supply disruptions in Saudi Arabia, and that NUPCO tender awards had been delayed, with results expected shortly.

Pipeline and launches: filings, approvals, and a push into complexity

Gland continued to add filings and approvals in the US. In Q1 FY27, the company filed three ANDAs and received seven ANDA approvals. The cumulative count stood at 389 filings, with 342 approved and 47 pending. It also launched four molecules in the US during the quarter.

The company’s strategy, as described in both documents, is to keep a strong base of sterile injectables while building a differentiated pipeline. The investor presentation highlighted an in-house complex pipeline where six products have been launched and three more are lined up for approval. It also described 15 co-development products (seven 505(b)(2) and eight ANDAs) with commercialization anticipated to begin in FY28.

Ready-to-Use infusion bags are an important platform within this strategy. The company has filed 21 RTU bag products and received approvals for 18 so far, with 11 more under development. The presentation estimated the US market opportunity addressed by this RTU portfolio at about USD 644 million.

Strategic announcements: a large CDMO agreement, plus new platforms

The biggest incremental disclosure in the quarter was a strategic manufacturing and supply agreement with a global specialty pharma company. Management described it as a portfolio of sterile injectables across oncology and non-oncology, with manufacturing expected at Gland’s India sites. The agreement covers 55 SKUs, with scope to add more products.

Management said that once the portfolio is fully commercialized, annualized revenue potential could be about USD 90 to 100 million. The timeline is long. Technology transfer activities are planned for completion within two years, filings are expected to start next year, and revenues are expected to commence from calendar year 2029.

Two other announcements expand the company’s longer-term optionality.

First, Gland entered into a strategic collaboration with Neuland Laboratories for manufacturing sterile APIs for microparticle depot products. Management positioned this as strategic capacity creation in an area where few companies offer sterile API sterilization, and also relevant for its internal pipeline.

Second, Gland signed an in-licensing agreement with a China-based development company for a niche liposomal product for the US and European markets. Management said it would invest in a compounding suite, execute technology transfer, conduct a bioequivalence study and then file in the US. It also said meaningful revenue contribution from this opportunity is expected from FY30.

Margins, cash flows, and capex discipline

The margin expansion in Q1 FY27 was supported by a combination of product mix and operating efficiencies. Management cited improved capacity utilization, procurement initiatives, alternate sourcing and manufacturing optimization. Gross margin stayed stable at 65%, while EBITDA margin improved to 27%.

One nuance in the quarter was forex. The CFO stated there was a forex loss of INR 36 million in Q1 FY27, compared to a forex gain of INR 508 million in Q4 FY26. This explained part of the quarter-on-quarter decline in PAT.

Cash generation remained healthy. Cash flow from operations was INR 3,183 million in Q1 FY27. As of June 30, 2026, total cash and cash equivalents were INR 35,466 million, and net cash was INR 32,939 million.

Capex was INR 1,132 million in Q1 FY27. Management reiterated that it has commenced execution of the INR 2,000 crore capex program and said FY27 capex spend is expected to be around INR 550 crore. It also called out an immediate incremental capex of about INR 165 crore for an oncology isolator line, targeted for installation by January 2027.

Takeaways

Q1 FY27 showed a combination of base execution and strategic direction. The quarter delivered 20% revenue growth with an improvement in adjusted EBITDA margin to 28% and a 47% rise in PAT. The mix stayed balanced between CDMO and B2B, and the US market remained the primary growth driver.

The more important signal, however, came from the longer-cycle announcements. The 55-SKU strategic manufacturing agreement, with revenue expected from 2029, points to how management is positioning Gland as an end-to-end sterile manufacturing partner. Alongside this, RTU bags, sterile API collaboration for depot products and a liposomal in-licensing deal show the company is pushing deeper into differentiated injectables and drug delivery platforms.

Execution over the next few quarters will likely be watched through a practical lens: regulatory milestones such as the RTU bag line approval, the pace of capacity additions under the capex program, and steady improvement in Cenexi’s operating profile. The quarter does not remove risks, but it reinforces that the company is trying to build a longer runway rather than only maximizing the next quarter’s number.